Compounds for inhibiting LY6K and methods of using same

Patent metadata

Field	Value
Publication number	US-12134601-B2
Application number	US-201816762424-A
Country	US
Kind code	B2
Filing date	Nov 9, 2018
Priority date	Nov 9, 2017
Publication date	Nov 5, 2024
Grant date	Nov 5, 2024

Abstract

The present technology relates to compounds that inhibit human Ly6K and homologs thereof. Also disclosed are methods of using such compounds to: inhibit activity of a Ly6K protein in a cell; decrease migration, colony formation, and/or proliferation of a cell; modulate expression of a gene in a cell, reduce suppression of the immune response to cancer in a subject, decrease tumorigenic growth of a cancer in a subject, and treat or prevent in a subject a disorder mediated by Ly6K protein.

First claim

What is claimed is:

1. A method for inhibiting Ly6K protein in a subject in need thereof, comprising administering to the subject:
(i) an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, or
(ii) an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, or
(iii) an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and
an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof,
wherein the effective amount is sufficient to lower activity of the Ly6k protein in the subject.

2. The method of claim 1 , comprising administering to the subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , comprising administering to the subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , comprising administering to the subject:
an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and
an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

5. A method for treating a disorder mediated by Ly6K protein in a subject in need thereof, comprising administering to the subject:
(i) an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, or
(ii) an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and
an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , comprising administering to the subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 5 , comprising administering to the subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and
an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 5 , wherein the disorder is a triple negative breast cancer, mesenchymal breast cancer, basal breast cancer, or immunomodulatory breast cancer.

Assignees

• Henry M Jackson Found Advancement Military Medicine Inc

Inventors

• Upadhyay Geeta

Classifications

• C07C39/15

  with all hydroxy groups on non-condensed rings {, e.g. phenylphenol} · CPC title

• A61K31/05

  Phenols {(cannabinoids A61K31/658)} · CPC title

• C07D219/10 Primary

  attached in position 9 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P35/00

  Antineoplastic agents · CPC title